Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Tzouvelekis, G. Zacharis, A. Oikonomou, K. Arcontogeorgis, A. Koulelidis, P. Boglou, M. Froudarakis, D. Mikroulis, D. Bouros (Alexandroupolis, Greece). Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE). Eur Respir J 2012; 40: Suppl. 56, 3150

Member's Comments

No comment yet.

Related content which might interest you: Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2014 – ILDs 1 Year: 2014 Acute exacerbation in combined pulmonary fibrosis and emphysema (CPFE): what special features? Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases Year: 2020 Comorbidities in patients with the combined pulmonary fibrosis and emphysema syndrome (CPFE) Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Comparison of clinical characteristics and prognostic factors between combined pulmonary fibrosis and emphysema/UIP versus non-UIP Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Combined pulmonary fibrosis and emphysema syndrome (CFPE) Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012 Mortality in combined pulmonary fibrosis and emphysema patients is determined by the sum of pulmonary fibrosis and emphysema Source: ERJ Open Res, 7 (3) 00316-2021; 10.1183/23120541.00316-2021 Year: 2021 Handigrip strenght and dynapenia in patients with idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Source: Eur Respir J 2005; 26: 586-593 Year: 2005